These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
366 related articles for article (PubMed ID: 34432543)
41. A primer on medicinal cannabis safety and potential adverse effects. Arnold JC Aust J Gen Pract; 2021 Jun; 50(6):345-350. PubMed ID: 34059837 [TBL] [Abstract][Full Text] [Related]
42. Cannabis for the Treatment of Epilepsy: an Update. Gaston TE; Szaflarski JP Curr Neurol Neurosci Rep; 2018 Sep; 18(11):73. PubMed ID: 30194563 [TBL] [Abstract][Full Text] [Related]
43. Implications of the endocannabinoid system and the therapeutic action of cannabinoids in autism spectrum disorder: A literature review. de Camargo RW; de Novais Júnior LR; da Silva LM; Meneguzzo V; Daros GC; da Silva MG; de Bitencourt RM Pharmacol Biochem Behav; 2022 Nov; 221():173492. PubMed ID: 36379443 [TBL] [Abstract][Full Text] [Related]
44. Pharmacological and dietary-supplement treatments for autism spectrum disorder: a systematic review and network meta-analysis. Siafis S; Çıray O; Wu H; Schneider-Thoma J; Bighelli I; Krause M; Rodolico A; Ceraso A; Deste G; Huhn M; Fraguas D; San José Cáceres A; Mavridis D; Charman T; Murphy DG; Parellada M; Arango C; Leucht S Mol Autism; 2022 Mar; 13(1):10. PubMed ID: 35246237 [TBL] [Abstract][Full Text] [Related]
45. Medication Use in the Management of Comorbidities Among Individuals With Autism Spectrum Disorder From a Large Nationwide Insurance Database. Feroe AG; Uppal N; Gutiérrez-Sacristán A; Mousavi S; Greenspun P; Surati R; Kohane IS; Avillach P JAMA Pediatr; 2021 Sep; 175(9):957-965. PubMed ID: 34097007 [TBL] [Abstract][Full Text] [Related]
46. Perceived efficacy of cannabidiol-enriched cannabis extracts for treatment of pediatric epilepsy: A potential role for infantile spasms and Lennox-Gastaut syndrome. Hussain SA; Zhou R; Jacobson C; Weng J; Cheng E; Lay J; Hung P; Lerner JT; Sankar R Epilepsy Behav; 2015 Jun; 47():138-41. PubMed ID: 25935511 [TBL] [Abstract][Full Text] [Related]
47. Safety and efficacy of low-dose medical cannabis oils in multiple sclerosis. S G; Hb S; K L; R T; Bs R; Ps S; F S; Ab O Mult Scler Relat Disord; 2021 Feb; 48():102708. PubMed ID: 33387864 [TBL] [Abstract][Full Text] [Related]
48. Cannabis for the treatment of Crohn's disease. Kafil TS; Nguyen TM; MacDonald JK; Chande N Cochrane Database Syst Rev; 2018 Nov; 11(11):CD012853. PubMed ID: 30407616 [TBL] [Abstract][Full Text] [Related]
49. Medicinal Cannabis for Paediatric Developmental, Behavioural and Mental Health Disorders. Efron D; Taylor K Int J Environ Res Public Health; 2023 Apr; 20(8):. PubMed ID: 37107712 [TBL] [Abstract][Full Text] [Related]
50. Oral Cannabidiol Use in Children With Autism Spectrum Disorder to Treat Related Symptoms and Co-morbidities. Barchel D; Stolar O; De-Haan T; Ziv-Baran T; Saban N; Fuchs DO; Koren G; Berkovitch M Front Pharmacol; 2018; 9():1521. PubMed ID: 30687090 [No Abstract] [Full Text] [Related]
51. Cannabinoid treatment for autism: a proof-of-concept randomized trial. Aran A; Harel M; Cassuto H; Polyansky L; Schnapp A; Wattad N; Shmueli D; Golan D; Castellanos FX Mol Autism; 2021 Feb; 12(1):6. PubMed ID: 33536055 [TBL] [Abstract][Full Text] [Related]
52. An update on pharmacotherapy of autism spectrum disorder in children and adolescents. Goel R; Hong JS; Findling RL; Ji NY Int Rev Psychiatry; 2018 Feb; 30(1):78-95. PubMed ID: 29693461 [TBL] [Abstract][Full Text] [Related]
53. UK Medical Cannabis Registry: an analysis of clinical outcomes of medicinal cannabis therapy for generalized anxiety disorder. Ergisi M; Erridge S; Harris M; Kawka M; Nimalan D; Salazar O; Loupasaki K; Ali R; Holvey C; Coomber R; Platt M; Rucker JJ; Sodergren MH Expert Rev Clin Pharmacol; 2022 Apr; 15(4):487-495. PubMed ID: 34937473 [TBL] [Abstract][Full Text] [Related]
54. Substituting Cannabidiol for Opioids and Pain Medications Among Individuals With Fibromyalgia: A Large Online Survey. Boehnke KF; Gagnier JJ; Matallana L; Williams DA J Pain; 2021 Nov; 22(11):1418-1428. PubMed ID: 33992787 [TBL] [Abstract][Full Text] [Related]
55. Feasibility of a cannabidiol-dominant cannabis-based medicinal product for the treatment of long COVID symptoms: A single-arm open-label feasibility trial. Thurgur H; Lynskey M; Schlag AK; Croser C; Nutt DJ; Iveson E Br J Clin Pharmacol; 2024 Apr; 90(4):1081-1093. PubMed ID: 38105651 [TBL] [Abstract][Full Text] [Related]
57. Effects of cannabidiol on anandamide levels in individuals with cannabis use disorder: findings from a randomised clinical trial for the treatment of cannabis use disorder. Hua DY; Hindocha C; Baio G; Lees R; Shaban N; Morgan CJ; Mofeez A; Curran HV; Freeman TP Transl Psychiatry; 2023 Apr; 13(1):131. PubMed ID: 37085531 [TBL] [Abstract][Full Text] [Related]
58. The psychopharmacology algorithm project at the Harvard South Shore Program: An algorithm for core symptoms of autism spectrum disorder in adults. Gannon S; Osser DN Psychiatry Res; 2020 May; 287():112900. PubMed ID: 32179209 [TBL] [Abstract][Full Text] [Related]
59. Autism Spectrum Disorder and Complementary-Integrative Medicine. Vandana P; Simkin DR; Hendren RL; Arnold LE Child Adolesc Psychiatr Clin N Am; 2023 Apr; 32(2):469-494. PubMed ID: 37147047 [TBL] [Abstract][Full Text] [Related]